(Q46614351)
English
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acu
scientific article published on 8 April 2005
Statements
Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia (English)
Patrice Chevallier
Virginie Roland
Béatrice Mahé
Nadine Juge-Morineau
Viviane Dubruille
Thierry Guillaume
Stéphane Vigouroux
Richard Garand
Jean-Luc Harousseau
8 April 2005